Latest Regulatory Filings News

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Laramide Resources Ltd. has acknowledged a delayed filing of a director's interest notice due to internal illness, prompting an ASX inquiry and procedural upgrades to prevent future lapses.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Predictive Discovery Limited has successfully completed a A$69.2 million strategic placement with key investors Lundin family and Zijin Mining Group, strengthening its financial position for future growth.

Pro-Pac Packaging has updated its quarterly cash flow report, highlighting a net cash outflow from operations and outlining plans to improve margins and secure longer-term funding.

Inventis Limited updates its operational review with corrected financials, securing major orders and pursuing significant capital raises to fuel international expansion.

BlinkLab has secured North Shore Pediatric Therapy as the second US clinical site in its autism diagnostic study, enhancing recruitment and data quality with a leading Chicago-based specialist.

CLINUVEL has released preliminary data from its CUV052 study showing SCENESSE® is well tolerated in adolescent erythropoietic protoporphyria (EPP) patients, supporting a planned label extension in 2025.

Gladiator Resources Limited reported a $703,000 net cash outflow for the December 2024 quarter, driven by exploration and evaluation expenses, yet maintains sufficient capital to fund operations into 2025.

Carnaby Resources has completed the settlement of Tranche 2 of its recent share placement, issuing 13.5 million new shares to raise approximately $4.2 million, including participation from its board members.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.